OUR MAIN STEM CELL PRODUCT FOR DISEASE TREATMENT, PREVENTION, AND ANTI–AGING
● Kintaro Cells are:
● Adult Stem Cells (MSC)
● From Bone Marrow Stroma
● Allogeneic (From Young and Healthy Screened Donors)
● Non–hematopoietic [CD34 – ] (Safe to use from donor)
● Made in our Tokyo laboratory
● Made with our patented cultivating methods 幹細胞培養方法
As the Kintaro Cells grow and multiply, they produce unique nutrients, peptides, and amino acids which remain in the medium. After the Kintaro Cells are extracted, the medium has been “ENRICHED” by growth factors and cytokines excreted by the Kintaro Cells.
Composition Cytokines and growth factors: IL-1 α, 6, 7, 8, 11, 12, 14, 15; LIF, FSC, Flt-3.M
The molecules of the extracellular matrix: Collagen types: I, III, IV, V, VI, fibronectin, laminin, hyaluronic acid, proteoglycans.
Vitamins: D-Biotin, Folic Acid, D-Pantothenic Acid Calcium Salt, Vitamin B1, Vitamin B2, Vitamin B12.
DENDRITIC + N.K CELLS for Cancer Treatment in Japan
Hybrid multi-peptide (4 peptides) DC vaccine and new NK-therapy, 5-fold injection with 14 days interval
DC – dendritic cells – is a population of antigen-presenting cells of medullary origin with a unique ability to induce primary immune responses. The main functions of DC are antigen presentation to lymphocytes, control over the differentiation of T- lymphocytes, regulation of immune responses. DC capture from the environments different antigens, process and represent on the surface in complex with MHC I or MHC II classes. Only in this form, T-cells are able to recognize the antigen and then activate and develop an immune response. NK – natural killers, natural killers are lymphocytes that have cytotoxicity against tumor cells and cells. The main function of NK is the destruction of cells of the body that do not carry MHC1 on their surface and therefore are inaccessible to T-killers.
DELIVERING THE SKILLS, TRAINING, AND TECHNOLOGY USED IN OUR TOKYO LAB TO YOUR COUNTRY
Kintaro Cells Power Corporation is able to transfer our patented cultivating methods, processing technology, and provide training in order to create new laboratories abroad with the same functioning capabilities as our home lab in Tokyo.
We have already replicated this process in Moscow, and will soon be opening a new lab in Hong Kong in 2018